← All trials
NCT06920147
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2025
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Apr 9, 2025
- Last posted
- Apr 11, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonSponsor investigator
- University of Texas at HoustonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.